On September 30, United Therapeutics surged 11.53% in regular trading, trading at $542.36/share with turnover of $477 million, marking its largest single-day gain since March. The rally was driven by a cluster of recent positive developments spanning key pipeline milestones and capital return initiatives.

On the regulatory front, the FDA formally accepted the company's supplemental new drug application for nebulized Tyvaso inhalation solution to treat idiopathic pulmonary fibrosis (IPF), with a review completion target of late April 2027. The filing was supported by combined analyses from two Phase 3 studies demonstrating statistically significant superiority over placebo. If approved, nebulized Tyvaso would become the first inhaled antifibrotic therapy for IPF in the US. Separately, the FDA also accepted a new drug application for ralinepag to treat pulmonary arterial hypertension, with a target action date of June 24, 2027, based on Phase 3 data showing a 55% reduction in clinical worsening risk.

Adding to the momentum, the company announced an accelerated share repurchase agreement with Citibank for $477.6 million, completing its $2 billion buyback authorization and bringing total shareholder returns to $4 billion over 2.5 years.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)